ID   397-mel
AC   CVCL_8050
SY   397-MEL; 397-Mel; 397 mel; 397mel; 397
DR   cancercelllines; CVCL_8050
DR   CGH-DB; 9295-4
DR   Cosmic; 876699
DR   Cosmic; 905209
DR   Cosmic; 897736
DR   Cosmic; 1295344
DR   Wikidata; Q54585254
RX   PubMed=8027550;
RX   PubMed=8081556;
RX   PubMed=8537970;
RX   PubMed=9670966;
RX   PubMed=9759882;
RX   PubMed=10048982;
RX   PubMed=10754339;
RX   PubMed=11121133;
RX   PubMed=15467732;
RX   PubMed=19799798;
RX   PubMed=21424129;
RX   PubMed=29492214;
CC   From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   HLA typing: A*01,25 (PubMed=9670966).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732).
CC   Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 23
//
RX   PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225;
RA   Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R.,
RA   Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K.,
RA   Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.;
RT   "Loss of HLA haplotype and B locus down-regulation in melanoma cell
RT   lines.";
RL   J. Immunol. 153:1225-1237(1994).
//
RX   PubMed=8081556; DOI=10.1097/00002371-199407000-00002; PMCID=PMC2561308;
RA   Marincola F.M., Shamamian P., Simonis T.B., Abati A.D., Hackett J.A.,
RA   O'Dea T., Fetsch P.A., Yannelli J.R., Restifo N.P., Mule J.J.,
RA   Rosenberg S.A.;
RT   "Locus-specific analysis of human leukocyte antigen class I expression
RT   in melanoma cell lines.";
RL   J. Immunother. Emphasis Tumor Immunol. 16:13-23(1994).
//
RX   PubMed=8537970; DOI=10.1093/jnci/88.2.100; PMCID=PMC2248456;
RA   Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K.,
RA   Yannelli J.R., Rosenberg S.A.;
RT   "Loss of functional beta 2-microglobulin in metastatic melanomas from
RT   five patients receiving immunotherapy.";
RL   J. Natl. Cancer Inst. 88:100-108(1996).
//
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N.,
RA   Panelli M.C., Parker K.K., Marincola F.M.;
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
//
RX   PubMed=9759882; DOI=10.4049/jimmunol.161.7.3596;
RA   Wang R.-F., Johnston S.L., Zeng G., Topalian S.L.,
RA   Schwartzentruber D.J., Rosenberg S.A.;
RT   "A breast and melanoma-shared tumor antigen: T cell responses to
RT   antigenic peptides translated from different open reading frames.";
RL   J. Immunol. 161:3596-3606(1998).
//
RX   PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A; PMCID=PMC2072935;
RA   Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A.,
RA   Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.;
RT   "Natural variation of the expression of HLA and endogenous antigen
RT   modulates CTL recognition in an in vitro melanoma model.";
RL   Int. J. Cancer 80:781-790(1999).
//
RX   PubMed=10754339; DOI=10.4049/jimmunol.164.8.4382;
RA   Panelli M.C., Bettinotti M.P., Lally K., Ohnmacht G.A., Li Y.,
RA   Robbins P.F., Riker A., Rosenberg S.A., Marincola F.M.;
RT   "A tumor-infiltrating lymphocyte from a melanoma metastasis with
RT   decreased expression of melanoma differentiation antigens recognizes
RT   MAGE-12.";
RL   J. Immunol. 164:4382-4392(2000).
//
RX   PubMed=11121133; DOI=10.1046/j.1523-1747.2000.00199.x;
RA   Lacal P.M., Failla C.M., Pagani E., Odorisio T., Schietroma C.,
RA   Falcinelli S., Zambruno G., D'Atri S.;
RT   "Human melanoma cells secrete and respond to placenta growth factor
RT   and vascular endothelial growth factor.";
RL   J. Invest. Dermatol. 115:1000-1007(2000).
//
RX   PubMed=15467732; DOI=10.1038/sj.onc.1208152;
RA   Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J.,
RA   Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.;
RT   "Involvement of overexpressed wild-type BRAF in the growth of
RT   malignant melanoma cell lines.";
RL   Oncogene 23:8796-8804(2004).
//
RX   PubMed=19799798; DOI=10.1186/1471-2407-9-352; PMCID=PMC2763007;
RA   Casula M., Muggiano A., Cossu A., Budroni M., Caraco C.,
RA   Ascierto P.A., Pagani E., Stanganelli I., Canzanella S., Sini M.C.,
RA   Palomba G., Palmieri G.;
RG   Italian Melanoma Intergroup (IMI);
RT   "Role of key-regulator genes in melanoma susceptibility and
RT   pathogenesis among patients from South Italy.";
RL   BMC Cancer 9:352.1-352.11(2009).
//
RX   PubMed=21424129; DOI=10.3892/or.2011.1220;
RA   Manca A., Sini M.C., Izzo F., Ascierto P.A., Tatangelo F., Botti G.,
RA   Gentilcore G., Capone M., Mozzillo N., Rozzo C., Cossu A., Tanda F.,
RA   Palmieri G.;
RT   "Induction of arginosuccinate synthetase (ASS) expression affects the
RT   antiproliferative activity of arginine deiminase (ADI) in melanoma
RT   cells.";
RL   Oncol. Rep. 25:1495-1502(2011).
//
RX   PubMed=29492214; DOI=10.18632/oncotarget.23989; PMCID=PMC5823576;
RA   Sini M.C., Doneddu V., Paliogiannis P., Casula M., Colombino M.,
RA   Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.;
RT   "Genetic alterations in main candidate genes during melanoma
RT   progression.";
RL   Oncotarget 9:8531-8541(2018).
//